You are here

Article Text

Article menu
Download PDFPDF
Letter
Cyclodiode treatment of neovascular glaucoma secondary to Coats’ disease
  1. D J de Silva,
  2. J L Brookes
  1. Moorfields Eye Hospital, London, UK
  1. Correspondence to: MrJ L Brookes Moorfields Eye Hospital, City Road, London EC1V 2PD, UK;john.brookes{at}moorfields.nhs.uk

https://doi.org/10.1136/bjo.2006.097121

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Coats’ disease is characterised by an idiopathic retinal telangiectasia and exudative retinopathy, which may lead to retinal detachment.1–3 In 10% of eyes, neovascular glaucoma may occur and these eyes have been treated with primary enucleation.2,4 Although enucleation is an effective means of relieving severe ocular pain, it may remove an eye with some visual potential and postoperative complications occur in approximately 50% of cases.5,6 We report the first use of cyclodiode laser treatment in three consecutive patients with neovascular glaucoma secondary to advanced Coats’ disease.

    Method

    Three patients with neovascular glaucoma secondary to Coats’ disease presented to the Glaucoma Service at Moorfields Eye Hospital, London, UK, between 2004 and 2005. Table 1 summarises the characteristics of …

    View Full Text

    Footnotes

    • Competing interests: None declared.